August 2026 FDA Warning Letters to Peptide Sellers: How “Research Use Only” Is Being Read
Four warning letters dated August 24, 2026 spell out when FDA treats a research-use-only peptide as an unapproved drug. The label is not the test.
Tagged
regulation
4 notes in this topic
The July 2026 FDA Advisory Votes on BPC-157, TB-500, MOTS-c and Semax: What Changed and What Did Not
An FDA advisory committee recommended six peptides for the 503A compounding list in July 2026. Here is what a non-binding vote does, and does not, mean.
FDA’s 2026 Move to Bar Bulk Compounding of GLP-1 Drugs: What It Means for Research Suppliers
In 2026 FDA moved to end bulk compounding of GLP-1 drugs and began citing research-labeled sellers of the same peptides. The two stories are one story.
Research Peptides Explained: What “Research Use Only” Actually Means
Where the RUO label comes from, how FDA views unapproved drugs and intended use, and why research peptide suppliers ask for researcher affirmations.
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.